25.08.2022 - Continued development of MP0317, with initial clinical data from Phase 1 study expected in the second half of 2022Initiation of Phase 1 study for MP0533 expected by year endContinued progression of proprietary DARPin-conjugated radioligand .
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Aug. 18, 2022 Molecular Partners AG , a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin. | August 18, 2022
Molecular Partners Announces Publication in Nature Biotechnology Detailing Design and Mechanism of Ensovibep DARPin Antiviral for SARS-CoV-2 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Molecular Partners Announces Participation in Scientific Conferences forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.
Evolva Holding SA / Key word(s): Miscellaneous Evolva business update: On track to reach 2022 guidance 19-May-2022 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer